Pieris Pharmaceuticals, Inc. is a clinical-staged biotechnology company advancing its proprietary Anticalin® technology to create differentiated drugs that are safer and more effective than conventional approaches. Exclusive to Pieris, Anticalin proteins promise to address high-unmet medical needs and expand the potential of targeted therapeutics. The company currently has a diverse proprietary pipeline and has ongoing R&D collaborations with Daiichi Sankyo, the Sanofi Group, Zydus Cadila, Stelis Biopharma and Allergan. Pieris has been funded by premier biotechnology-focused venture capital, including lead investors OrbiMed Advisors and Global Life Science Ventures.
View our latest fact sheetView Presentation
255 State Street
Boston, MA 02109 US
+49 (0) 8161 14 11 400
+49 (0) 8161 14 11 444
541711 (Research and Development in Biotechnology)